Level C· Early human research exploring benefitsCohort StudyEurope PMCOpen access

Exploration common biomarkers and pathogenesis of primary Sjögren's syndrome and interstitial lung disease by machine learning and weighted gene co-expression networks

Dong J., Wang Z., Xu Y., Liang S.

Cohort Study on Autoimmune Research, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
PLoS One (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41052072
PMCID
PMC12500160
DOI
10.1371/journal.pone.0333070
Citations
2

Abstract (original English)

Background Primary Sjögren's syndrome (pSS) is an autoimmune and inflammatory disorder that may affect the lungs, leading to interstitial lung disease (ILD). However, the diagnosis of progression from pSS to ILD is frequently delayed due to unstandardized interdisciplinary diagnostic criteria and a lack of reliable shared biomarkers. This diagnostic challenge, compounded by significant pathophysiological divergence in target organs, has hindered elucidation of their comorbidity mechanisms. This study employs integrated bioinformatics to identify shared biomarkers in pSS and ILD, deciphers their pathogenic mechanisms, and predicts targeted therapeutics via network pharmacology. Methods From the Gene Expression Omnibus (GEO) database, we retrieved gene expression profiles of pSS and ILD. Differential expression gene (DEG) analysis was performed on the profiles, followed by further screening using four machine learning algorithms. Concurrently, weighted gene co-expression network analysis (WGCNA) was applied to identify gene modules, and enrichment analysis of WGCNA-derived genes was conducted to explore their biological functions. Genes obtained from WGCNA and machine learning approaches were then intersected to identify candidate biomarkers for pSS-ILD. The diagnostic potential of these candidate genes was evaluated in both discovery and validation sets using receiver operating

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansSjogren's SyndromeLung Diseases, InterstitialGene Expression ProfilingComputational BiologyGene Regulatory NetworksTranscriptomeBiomarkersMachine Learning

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research